Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Bashar Abuqayas
Observed name:
Bashar Abu Qayas
Institutions:
University of Iowa,
King Hussein Cancer Center,
University of Iowa Hospitals and Clinics,
University of Iowa Health Care,
University of Iowa Holden Comprehensive Cancer Center
Observed institutions:
Seton Hall University,
University of Iowa,
King Hussein Cancer Center,
University of Iowa Hospitals and Clinics,
Trinitas Regional Medical Center,
University of Iowa Health Care,
University of Iowa Holden Comprehensive Cancer Center
show all 7
ORCID:
0000-0002-9258-8299
Observed ORCID:
0000-0002-9258-8299
OpenAlex ID:
A5026551466
Clinical Activity and Safety of Cabozantinib for Brain Metastases in Patients With Renal Cell Carcinoma
2021
·
Laure Hirsch
, Nieves Martinez Chanza
, et al.
·
JAMA Oncology
·
100
PDF
Psychometric properties of the Arabic version of EORTC QLQ-C15-PAL among cancer patients in Jordan
2015
·
Alia Alawneh
, Hesham Yasin
, et al.
·
Supportive Care in Cancer
·
27
Intensity of Cancer Care Near the End of Life at a Tertiary Care Cancer Center in Jordan
2019
·
Hikmat Abdel-Razeq
, Omar Shamieh
, et al.
·
Journal of Pain and Symptom Management
·
18
PDF
Azacitidine-induced cryptogenic organizing pneumonia: a case report and review of the literature
2016
·
Yanal Alnimer
, Samer Salah
, et al.
·
Journal of Medical Case Reports
·
18
PDF
Treatment‐Related Adverse Events and Associated Outcomes in Patients With Advanced Urothelial Carcinoma Treated With Enfortumab Vedotin: Analysis of the UNITE Study
2025
·
Amanda Nizam
, Charles B. Nguyen
, et al.
·
Cancer Medicine
·
16
Real-World Outcomes of Patients With Baseline Neuropathy and/or Diabetes Mellitus Receiving Enfortumab Vedotin-Based Regimens for Advanced Urothelial Carcinoma in the UNITE Database
2026
·
Albert Jang
, Tanya Jindal
, et al.
·
Clinical Genitourinary Cancer
·
3
Efficacy of erdafitinib before or after enfortumab vedotin in FGFR3 -altered advanced urothelial cancer: analysis of the UNITE collaborative study
2025
·
Cindy Y Jiang
, Hyunsoo Hwang
, et al.
·
The Oncologist
·
3
PDF
Phase I with expansion clinical trial of seleno-l-methionine (SLM) in combination with axitinib in patients with relapsed clear cell renal cell carcinoma (ccRCC): Bench to bedside.
2021
·
Yousef Zakharia
, Ryan Reis
, et al.
·
Journal of Clinical Oncology
·
2
Corrigendum to ‘Intensity of Cancer Care Near the End-of-Life at a Tertiary Care Cancer Center in Jordan’ [Journal of Pain and Symptom Management 57 (2019) 1106–1113]
2026
·
Hikmat Abdel-Razeq
, Omar Shamieh
, et al.
·
Journal of Pain and Symptom Management
PDF
REFINE: a database of linked clinical data and genomic biomarkers in renal cell carcinoma patients receiving immunotherapy-based treatment regimens
2025
·
Jeffrey Zhong
, Albert Jang
, et al.
·
The Oncologist
PDF
Show more works
View as search
Works count:
10
Citation count:
187
H-index:
5
I10-index:
5
Year
Topic
Type